Prognosis
Race for Virus Cure Hits Reality as Complications Mount
- Fast-moving studies hit bumps often seen in other research
- Pauses for Lilly, J&J candidates come amid intense scrutiny
This article is for subscribers only.
The sprint to find medical breakthroughs to contain Covid-19 stumbled this week, as a pair of pharmaceutical giants working to develop treatments and vaccines suffered setbacks in the clinic.
On Tuesday, Eli Lilly & Co. said that enrollment in a government-sponsored clinical trial of its antibody therapy had been paused out of safety concerns. That came less than 24 hours after Johnson & Johnson said research on its experimental vaccine was paused after a study volunteer fell ill.